Lincoln Pharmaceuticals Limited has reported net profit of Rs. 11.85-crore in Q4FY21 as against net profit of Rs. 9.23-crore in the corresponding period last year, growth of 28.33%. Net revenue from operations in Q4FY21 was reported at Rs. 77.54-crore, higher by 3.03% over previous fiscal’s same period net revenue from operations of Rs. 75.26-crore. Company reported EBITDA of Rs. 16.74-crore in Q4FY21, rise of 28.25% as compared to Rs. 13.05-crore in the corresponding period last year. EPS for Q4FY21 was at Rs. 5.92 per share as compared to Rs. 4.62 in the corresponding period last year. Company has recommended dividend of 15% – Rs. 1.50 per share on the face value of Rs. 10 per share.
During the fiscal, promoter group of Lincoln Pharmaceuticals Ltd increased holding in the company to 37.25% – rise of 4.9% (490 bps) from 32.36% as of 31 March 2020. Promoter group bought 9.8-lakh shares from the secondary market during the year. Company plans to enter the EU markets in FY22 with its dermatology, gastro and pain management products. Company currently exports to more than 60 countries and plans to expand to 90 plus countries. Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, complying with stringent international quality and compliance norms. Company has developed 600 plus formulations in 15 therapeutic areas. Company has a strong presence in domestic market with good strength of own field force and also exports to more than 60 countries.
